|
Recent Developments |
|
11-FEB-19
Pharma major Lupin announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Goa manufacturing facility. The inspection was carried out between January 28 to February 8, 2019.
07-FEB-19
Pharma major Lupin announced that it has received approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Compan... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Lupin Ltd is focusing on manufacturing products with high technology barriers through the non-infringing route. D. B. Gupta |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015 (12) | 31-Mar-2014(12) | | Net sales | 108100.10 | 96115.40 | 87771.80 | | Other Income | 1938.80 | 1806.30 | 4882.20 | | Total Income | 110038.90 | 97921.70 | 92654.00 | | Cost of goods sold | 72480.10 | 63792.20 | 60998.90 | | OPBDIT | 37558.80 | 34129.50 | 31655.10 | | PAT | 28850.70 | 23973.50 | 23242.20 | | Gross Block | - | - | - | | Equity capital | 901.20 | 899.00 | 896.80 | | EPS (Rs.) | - | 53.41 | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 16.92 - 38.14 | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 34.1 | 34.9 | 34.2 | | Net margin (% of OI) | 26.2 | 24.5 | 25.1 |
|
|
Detailed Financials
|
|
|
|
|
